RT Journal Article
SR Electronic
T1 Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4841
DO 10.1183/13993003.congress-2016.PA4841
VO 48
IS suppl 60
A1 Cherif, Hela
A1 Bacha, Saoussen
A1 Habibech, Sonia
A1 Racil, Hager
A1 Cheikhrouhou, Sana
A1 Chaouech, Naouel
A1 Chabbou, Abdellatif
A1 Megdiche, Mohamed Lamine
YR 2016
UL https://publications.ersnet.org//content/48/suppl_60/PA4841.abstract
AB Introduction: Cytotoxic chemotherapy is widely used to palliate advanced non-small-cell lung cancer (NSCLC) but can induce severe toxic events. The aim of this study was to evaluate the chemotherapy toxicity in adavanced non-small cell lung cancer (NSCLC) and its impact on overall survival (OS).Methods: We retrospectively reviewed 99 advanced stage NSCLC patients treated with chemotherapy over a period of 3 years. Pre-therapeutic clinical and biological data were assessed. OS was calculated using the Kaplan Meier method and compared between two groups (having or not toxicity) by log rank test.Results: Median age was 65 years, 84% of patients had Performans status (PS) <2, 28% were malnourished (BMI <20 kg/m2). Anemia (Hb<12g/dL) and hypoalbuminemia were observed respectively in 30% and 10% of cases. Platinum chemotherapy regimen was used in 86% of cases. Seventy-eight percent of the patients has developed at least one chemotherapy related toxic event. Main toxicities were hematologic (47%; 26% of toxicity≥ grade 3), gastrointestinal (30%; 58% of toxicity ≥ grade 3) and renal (20%; 9% of toxicity ≥ grade 3). Eighty-five percent of toxic events occurred at the first line and on average over 1.7 th cycle. No toxic death event has happened. Patients with PS ≤2, anemia, malnutrition and hypoalbuminemia didn't developed more chemotherapy-induced toxicity (p=0.66; p =0.48; p=0.93; p=0.78 respectively). OS of patients with chemotherapy toxic event was 12.3 months compared with 7.51 months in patients without chemotherapy toxic event (logrank; p = 0.002).Conclusion: Our study suggested that Chemotherapy-induced toxicity in advanced NSCLC patients was associated with poor survival.